Virtu Financial’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Virtu Financial’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-27,598	Closed	-$1.36M	–	2358
2018 Q1	$1.36M	Sell	27,598 -29,876	-52%	-$1.52M	0.07%	259
2017 Q4	$2.71M	Buy	57,474 +44,913	+358%	+$2.11M	0.14%	120
2017 Q3	$627K	Sell	12,561 -1,877	-13%	-$89K	0.03%	738
2017 Q2	$659K	Sell	14,438 -4,352	-23%	-$188K	0.09%	184
2017 Q1	$795K	Buy	+18,790	New	+$788K	0.08%	167
2016 Q2	–	Sell	-33,323	Closed	-$1.28M	–	484
2016 Q1	$1.28M	Buy	33,323 +27,407	+463%	+$1.06M	0.18%	130
2015 Q4	$299K	Buy	+5,916	New	+$292K	0.04%	292
2015 Q3	–	Sell	-11,184	Closed	-$653K	–	378
2015 Q2	$653K	Sell	11,184 -12,200	-52%	-$698K	0.06%	177
2015 Q1	$1.29M	Buy	+23,384	New	+$1.26M	0.14%	102
2014 Q2	–	Sell	-45,444	Closed	-$1.89M	–	417
2014 Q1	$1.89M	Buy	+45,444	New	+$1.94M	0.26%	79

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Virtu Financial's PBE Position: Q2 2018 in Review

Virtu Financial sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2018, closing a stake of 27,598 shares — an estimated $1.36M sold.

Virtu Financial first reported a position in PBE in Q1 2014 and held it in 10 quarters. The position peaked at $2.71M in Q4 2017. 73 funds tracked by Wall St. Rank hold PBE as of Q2 2018.

Virtu Financial reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2018 after selling out during the quarter.
Virtu Financial sold 27,598 Invesco Biotechnology & Genome ETF shares in Q2 2018, an estimated $1.36M.
Virtu Financial first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 10 quarters.
Virtu Financial's Invesco Biotechnology & Genome ETF position peaked at $2.71M in Q4 2017.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2018.

Based on Virtu Financial's 13F filing for Q2 2018, filed 30 Jul 2018.